{"brief_title": "Pediatric Epilepsy Study", "brief_summary": "This study will evaluate the safety and effectiveness of oxcarbazepine (Trileptal) as monotherapy in the treatment of partial seizures in pediatric patients 1 month to 3 years of age.", "condition": ["Epilepsy"], "intervention_type": ["Drug"], "intervention_name": ["oxcarbazepine"], "criteria": "INCLUSION CRITERIA: To enter this study, patients must: - Have a diagnosis of partial seizures - Have 2-30 seizures per week while on a stable dose of one anti-epileptic drug or be a patient recently diagnosed with partial seizures and currently receiving no seizure medication - Be willing to be hospitalized for up to 5 days - Weigh a minimum of 6.6 lbs - Have had a previous CAT scan/MRI confirming the absence of space occupying lesions or progressive neurological disease - Have normal laboratory results EXCLUSION CRITERIA: To enter this study, a patient must not have or be: - Seizures caused by metabolic disturbance, toxic exposure, or active infection - A primary diagnosis of generalized epilepsy (exception - secondarily generalized seizures) - A history of status epilepticus within 30 days - Seizures not related to epilepsy - This study has some AED restrictions - Serum sodium levels <135 mEq/L - Significant heart, breathing, kidney, stomach, liver, blood, or cancer disorder requiring treatment/therapy - A history of chronic infection (e.g., hepatitis or HIV) - Significant electrocardiogram (ECG) abnormalities - A nursing mother taking anti-convulsant drugs - A history of substance abuse (including alcohol) - Previously demonstrated sensitivity/allergic reaction to Trileptal or related compounds - Used experimental medication within 30 days of entering this study", "gender": "All", "minimum_age": "1 Month", "maximum_age": "16 Years", "healthy_volunteers": "No", "keyword": "partial seizures", "mesh_term": ["Epilepsy", "Oxcarbazepine", "Carbamazepine"], "id": "NCT00050947"}